Literature DB >> 16001613

Expression pattern of telomerase reverse transcriptase in rectal carcinoma predicts tumor radiosensitivity, local recurrence and disease-free survival.

Yasuhiro Komuro1, Toshiaki Watanabe, Giichiro Tsurita, Tetsuichiro Muto, Hirokazu Nagawa.   

Abstract

BACKGROUND/AIMS: Predictive indicators of radiosensitivity in rectal cancer are required in order to avoid unnecessary preoperative radiotherapy. Telomeres are specialized structures at the ends of chromosomes that protect against that such as irradiation. Lower telomerase activity has been reported to be related to radiosensitivity in vitro or vivo. The aim of this study was to examine the possible role of telomerase reverse transcriptase expression, which is correlated to telomerase activity, in determining tumor radiosensitivity, local recurrence, and disease-free survival in patients with rectal carcinomas.
METHODOLOGY: We studied 96 cases with advanced rectal carcinoma. In preradiation biopsy specimens of tumor samples, the number of cells stained positive for telomerase reverse transcriptase protein was evaluated by immunohistochemistry.
RESULTS: The expression pattern of telomerase reverse transcriptase protein correlated with tumor radiosensitivity (P=0.0007). All tumors that had a high percentage of telomerase reverse transcriptase positive cells were radioresistant. High telomerase reverse transcriptase expression pattern is a predictive marker for high local recurrence or poor survival in patients with rectal cancer (P=0.011, P=0.0005). Telomerase reverse transcriptase expression and histopathological grade were significant prognostic variables for disease-free survival in the multivariate analysis (P=0.0003, P=0.0091).
CONCLUSIONS: Telomerase reverse transcriptase raises the predictive possibility of tumor radiosensitivity in rectal cancer. Telomerase reverse transcriptase might be a useful parameter for patient selection for preoperative radiotherapy in rectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001613

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer.

Authors:  Kazushige Kawai; Joji Kitayama; Nelson H Tsuno; Eiji Sunami; Hirokazu Nagawa
Journal:  Int J Colorectal Dis       Date:  2010-09-01       Impact factor: 2.571

2.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08

3.  Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer.

Authors:  Kazushige Kawai; Joji Kitayama; Nelson H Tsuno; Eiji Sunami; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2012-10-19       Impact factor: 2.571

4.  Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.

Authors:  Noriko Tada; Kazushige Kawai; Nelson H Tsuno; Soichiro Ishihara; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Koji Oba; Toshiaki Watanabe
Journal:  World J Surg Oncol       Date:  2015-02-07       Impact factor: 2.754

5.  Telomere profiling: toward glioblastoma personalized medicine.

Authors:  Sylvain Ferrandon; Paul Saultier; Julien Carras; Priscillia Battiston-Montagne; Gersende Alphonse; Michael Beuve; Céline Malleval; Jérôme Honnorat; Tania Slatter; Noelyn Hung; Janice Royds; Claire Rodriguez-Lafrasse; Delphine Poncet
Journal:  Mol Neurobiol       Date:  2012-10-12       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.